The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Ocrelizumab and rituximab, both anti-CD20 B-cell monoclonal antibodies, differ in molecular structure and safety profiles, impacting MS treatment outcomes. Retrospective data from the University of ...

Please provide your email address to receive an email when new articles are posted on . Rituximab- and cyclophosphamide-based remission induction for ANCA-associated vasculitis demonstrate similar ...